NCT05537038View on ClinicalTrials.gov

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

June 6, 2025

Study Completion Date

December 31, 2025

Conditions
Tuberculosis
Interventions
BIOLOGICAL

BNT164a1

Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

BIOLOGICAL

BNT164b1

Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

OTHER

Placebo

Placebo

Trial Locations (3)

10629

emovis GmbH, Berlin

13627

CRS Clinical Research Services Berlin GmbH, Berlin

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
lead

BioNTech SE

INDUSTRY